Teva sales and marketing update

Teva announced launches for two G-CSF products. In the U.S., the company launched Granix tbo-filgrastim, a short-acting recombinant form of G-CSF comparable to Neupogen filgrastim from Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.). Granix is approved to reduce the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. ...